Shenyang Xingqi Gains Nod for Eye Drop Candidate Clinical Study

Stock News

Yesterday

Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) has announced that it has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration for its SQ-23082 eye drop formulation. This approval permits the company to proceed with clinical trials for the candidate treatment.

The SQ-23082 eye drop is a Class 2.1 modified new drug developed by the company, intended for the treatment of eye itching associated with allergic conjunctivitis. Following the requirements for modified new drugs, the company has completed comprehensive research covering pharmaceutical chemistry and non-clinical pharmacological and toxicological evaluations, with results indicating favorable safety and significant clinical development potential.

According to the announcement, no similar ophthalmic preparation has yet been marketed domestically or internationally, positioning this candidate as a novel therapeutic option in the field.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/1198006960"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198006960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198006960?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-11 15:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198006960","market":"other","top_or_hot":-1,"title":"Shenyang Xingqi Gains Nod for Eye Drop Candidate Clinical Study","media":"Stock News","content":"<p><b>Shenyang Xingqi Pharmaceutical Co., Ltd.</b> (<b>300573.SZ</b>) has announced that it has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration for its SQ-23082 eye drop formulation. This approval permits the company to proceed with clinical trials for the candidate treatment.<br><br>The SQ-23082 eye drop is a Class 2.1 modified new drug developed by the company, intended for the treatment of eye itching associated with allergic conjunctivitis. Following the requirements for modified new drugs, the company has completed comprehensive research covering pharmaceutical chemistry and non-clinical pharmacological and toxicological evaluations, with results indicating favorable safety and significant clinical development potential.<br><br>According to the announcement, no similar ophthalmic preparation has yet been marketed domestically or internationally, positioning this candidate as a novel therapeutic option in the field.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenyang Xingqi Gains Nod for Eye Drop Candidate Clinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenyang Xingqi Gains Nod for Eye Drop Candidate Clinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-11 15:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shenyang Xingqi Pharmaceutical Co., Ltd.</b> (<b>300573.SZ</b>) has announced that it has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration for its SQ-23082 eye drop formulation. This approval permits the company to proceed with clinical trials for the candidate treatment.<br><br>The SQ-23082 eye drop is a Class 2.1 modified new drug developed by the company, intended for the treatment of eye itching associated with allergic conjunctivitis. Following the requirements for modified new drugs, the company has completed comprehensive research covering pharmaceutical chemistry and non-clinical pharmacological and toxicological evaluations, with results indicating favorable safety and significant clinical development potential.<br><br>According to the announcement, no similar ophthalmic preparation has yet been marketed domestically or internationally, positioning this candidate as a novel therapeutic option in the field.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0177","symbol_name":"最小市值","start_time":0,"source_url":"","article_id":"1198006960","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198006960","pubTimestamp":1789113496,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) has announced that it has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration for its SQ-23082 eye...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300573":"兴齐眼药","BK0177":"最小市值","PSYK":"PSYK ETF","BK0239":"医药制造","BMED":"iShares Health Innovation Active ETF","MDTX":"Corgi MediaTek 2x Daily ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"沈阳星旗眼药水候选临床研究获点名","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300573":1,"IBBJ":1,"MDTX":1,"PSYK":1,"BMED":1,"IBBQ":1},"content_text":"Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) has announced that it has received the Drug Clinical Trial Approval Notice from the National Medical Products Administration for its SQ-23082 eye drop formulation. This approval permits the company to proceed with clinical trials for the candidate treatment.The SQ-23082 eye drop is a Class 2.1 modified new drug developed by the company, intended for the treatment of eye itching associated with allergic conjunctivitis. Following the requirements for modified new drugs, the company has completed comprehensive research covering pharmaceutical chemistry and non-clinical pharmacological and toxicological evaluations, with results indicating favorable safety and significant clinical development potential.According to the announcement, no similar ophthalmic preparation has yet been marketed domestically or internationally, positioning this candidate as a novel therapeutic option in the field.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}